Cryo-EM and SPR Analysis of SARS-CoV-2 Spike Protein Neutralization by Cayman Antibody Complex
We made a SARS-CoV-2 (human) neutralizing recombinant antibody which disrupts S1 RBD-ACE2 interaction.
Read Case StudyOur structural biology experts have proven experience in biophysical characterization to advance your drug discovery, hit identification, hit-to-lead, and lead optimization efforts. We offer a variety of biophysical methods, including surface plasmon resonance (SPR), thermal shift assay (TSA), and dynamic light scattering (DLS), to help you characterize small molecules and proteins, understand molecular interactions and binding mechanisms, and optimize drug-target interactions. Our biophysical characterization services can be used as stand-alone services or incorporated into larger projects as part of Cayman’s suite of integrated drug discovery services.
We offer high-quality structure-function analysis, screening, and characterization of drug candidates, including small molecules, proteins, peptides, and lipid nanoparticles (LNPs), using the industry-leading BiacoreTM 8K. We can screen and rank order drug-protein and protein-protein interactions, measure interaction kinetics (Kon, Koff) and affinity (KD), and determine interactant concentrations in samples. Our SPR services can be utilized for a variety of applications, with several detailed below.
(Can be provided by either the customer or Cayman unless otherwise noted)
2 Weeks
2-4 Weeks
(up to 200 compounds)
2-4 Weeks
(up to 2,000 fragments)
$
$
$$
Case Study:
Cryo-EM and SPR Analysis of SARS-CoV-2 Spike Protein Neutralization by Cayman Antibody Complex
Scientific Poster:
Fragment-Based Drug Discovery (FBDD) Approach for TNF-α
TSA measures the thermal stability of proteins and offers qualitative assessment of compound binding.
We offer high-throughput DLS measurements of protein concentration, hydrodynamic size, and polydispersity, as well as detection of aggregates, using the Stunner by Unchained Labs.
This high-throughput, high-sensitivity SPR system delivers high-quality binding data for interaction analysis allowing ranking, kinetics, affinity, epitope binding, concentration, and relative potency. It enables efficient screening, characterization, process optimization, and quality control of small molecules and biotherapeutics.
Stunner is the only system that pulls together UV/Vis concentration, dynamic light scattering (DLS), and static light scattering (SLS) from the same 2 μl sample.
Our experienced scientists will analyze your data and provide reports reviewed by our quality assurance managers. SPR reports will include kinetics and affinity measurements, as well as full sensorgrams. For FBDD projects, we will also include a list of all fragment hits along with their 2D structures. TSA reports will include melting profiles and rank ordered hits. DLS reports will provide details about polydispersity index, mass distribution for particles, and absorbance.
We offer tiered pricing for projects characterizing more than 10 analytes. Tiered pricing is also available for 6- and 12-month small molecule and biologic (antibody) characterization contracts. For more information about our Biophysical Characterization services and project-specific pricing, please submit the “Contact Us” form.
Cayman offers comprehensive recombinant protein production services that include multiple expression platforms, purification methods, and characterization services to meet your project’s specific needs.
Our scientists can produce high-quality antigens and monoclonal, polyclonal, and recombinant antibodies suitable for a variety of applications.
Our experienced computational and medicinal chemists can perform rapid hit identification using virtual high-throughput screening backed by expertise in Schrödinger suite, followed by hit-to-lead and lead optimization through iterative, rational SAR studies, custom synthesis, and screening.
Our structural biology experts offer protein crystallization services and structure determination by X-ray crystallography and cryo-EM.
We made a SARS-CoV-2 (human) neutralizing recombinant antibody which disrupts S1 RBD-ACE2 interaction.
Read Case StudyWe perform crystallization studies that delivered multiple high-resolution crystal structures of LpxC.
Read Case StudyHere we describe the expression and two-step purification of the MR1 (K43A)/β2M stable complex.
View PosterIntegrated computational and biophysical approaches improve screening efficiency and finding hits in FBDD.
View PosterH-PGDS plays a role in both allergic and inflammatory diseases.
View PosterInvestigating ability of a SARS-CoV-2 nAb to block spike S1 RBD-ACE2 interaction using cryoEM and SPR.
View Poster
Guidelines for design and development of hSTING agonists research.
View Poster
We performed a high-throughput small molecule screen against GOT1.
View PosterRecombinant histone H3 can be citrullinated by PAD4 at 4°C with high yields.
View Poster